Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livoletide for food-related behaviors in Prader-Willi syndrome
NL-OMON48225Phase 2Completed
- Sponsor
- Millendo Therapeutics
- Start
- Aug 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of livoletide in Prader-Willi syndrome (PWS) (3 arms), sponsored by Millendo Therapeutics. Primary endpoint: Change in hyperphagia and food-related behaviors. Started Aug 2019; status: completed.
02
Drugs
livoletide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NL-OMON48225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48225.